



Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(use as many sheets as necessary)

Application Number	09/546,573
Filing Date	April 10, 2000
First Named Inventor	HOLTEN-ANDERSEN
Art Unit	1643
Examiner Name	S. L. Rawlings
Attorney Docket Number	59866.000002

Sheet 1 of 1

U.S. PATENT DOCUMENTS

*Examiner Initials	Cite No.	DOCUMENT NUMBER Number - Kind Code (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	1	US 2004/157278 A1	08/12/2004	Astle, et al.	
SR		US 2004/0157278 A1	8/12/2004	Astle, et al.	

FOREIGN PATENT DOCUMENTS

*Examiner Initial	Cite No.	FOREIGN PATENT DOCUMENT		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	TRANSLATION	
		Country Code:	Number - Kind Code (if known)				YES	NO
SR	2	EP	1171771	10/19/2000	Holten-Andersen, et al.			
SR	3	EP	1381631	10/31/2002	Pan, et al.		<input type="checkbox"/>	<input type="checkbox"/>

OTHER DOCUMENTS - NON-PATENT LITERATURE DOCUMENTS

*Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	TRANSLATION
			YES NO
			<input type="checkbox"/> <input type="checkbox"/>

EXAMINER SIGNATURE

DATE CONSIDERED

3/24/06

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



(use as many sheets as necessary)

09/546,573

April 10, 2000

Mads HOLTEN-ANDERSEN, et al.

1643

S. L. Rawlings

1 of 3

59866.000002

EXAMINER SIGNATURE

DATE CONSIDERED

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



Substitute for form 1449/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT***(use as many sheets as necessary)*

Application Number	09/546,573
Filing Date	April 10, 2000
First Named Inventor	Mads HOLTEN-ANDERSEN, et al
Art Unit	1643
Examiner Name	S. L. Rawlings
Attorney Docket Number	59866.000002

Sheet **2 of 3****OTHER DOCUMENTS - NON-PATENT LITERATURE DOCUMENTS**


Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	TRANSLATION	
			YES	NO
SR	2.	Agency for Health Care Policy and Research, "Colorectal Cancer Screening: Summary", Evidence Report: Number 1. AHCPR Publ. No. 97-0302, pg. 1-4.	<input type="checkbox"/>	<input type="checkbox"/>
	3.	Aznavorian S. et al., "Molecular Aspects of Tumor Cell Invasion and Metastasis", Cancer, 15, 71(4), pg. 1368-1383, 1993.	<input type="checkbox"/>	<input type="checkbox"/>
	4.	Balk, S. P. et al., "Biology of Neoplasia, Biology of Prostate-Specific Antigen", Journal of Clinical Oncology, 21 (2), pg. 383-391, 2003.	<input type="checkbox"/>	<input type="checkbox"/>
	5.	Benson, A. B., et al., "ASCO Special Article - 2000 Update of American Society Colorectal Cancer Surveillance Guidelines", Journal of Clinical Oncology, 18(20), pg. 3586-3588, October 15, 2000.	<input type="checkbox"/>	<input type="checkbox"/>
	6.	Birkedal-Hansen, "Role of Matrix Metalloproteinases in Human Periodontal Diseases", J. Periodontal., pg. 474-484, May 1993.	<input type="checkbox"/>	<input type="checkbox"/>
	7.	Breimer, D. D., et al., "Saliva: A Fluid for Measuring Drug Concentrations", Pharmacy International, 1, pg. 9-11, 1980.	<input type="checkbox"/>	<input type="checkbox"/>
	8.	Khokha, R. et al., "AntisenseRNA-Induced Reduction in Murine TIMP Levels Confers Oncogenicity on Swiss 3T3 Cells", Science, 243, pg. 947-950, February 17, 1989.	<input type="checkbox"/>	<input type="checkbox"/>
	9.	Kleiner, et al., "Stability Analysis of Latent and Active 72-kDa Type IV Collagenase: The Role of Tissue Inhibitor of Metalloproteinases-2 (TIMP-2)", Biochemistry, 32, pg. 1583-1592, 1993.	<input type="checkbox"/>	<input type="checkbox"/>
	10.	Lovgren, J., et al., "Measurement of Prostate-Specific Antigen and Human Glandular Kallikrein 2 in Different Body Fluids", J. Andrology, 20, pg. 348-355, 1999.	<input type="checkbox"/>	<input type="checkbox"/>
	11.	Remacle, A. et al., "High Levels of TIMP-2 Correlate with Adverse Prognosis in Breast Cancer", Int. J. Cancer, 89, pp: 118-121, 2000.	<input type="checkbox"/>	<input type="checkbox"/>
✓	12.	Stetler-Stevenson WG et al., "Matrix Metalloproteinases and Tumor Invasion: From Correlation and Causality to the Clinic", Semin. Cancer. Biol., 7, pp. 147-154, 1996.	<input type="checkbox"/>	<input type="checkbox"/>

EXAMINER SIGNATURE

DATE CONSIDERED

3/24/06

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Application Number	09/546,573
Filing Date	April 10, 2000
First Named Inventor	Mads HOLTEN-ANDERSEN, et al
Art Unit	1643
Examiner Name	S. L. Rawlings
Attorney Docket Number	59866.000002

Sheet 3 of 3

OTHER DOCUMENTS - NON-PATENT LITERATURE DOCUMENTS

Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	TRANSLATION	
			YES	NO
SR	13.	Turan T. et al., "Free and Total Prostate-Specific Antigen Levels in Saliva and the Comparison with Serum Levels in Men", Eur. Urol., 38(5), pp. 550-554, 2000.	<input type="checkbox"/>	<input type="checkbox"/>
	14.	Vignola et al., "Sputum Metalloproteinase-9/Tissue Inhibitor of Metalloproteinase-1 Ratio Correlates with Airflow Obstruction in Asthma and Chronic Bronchitis", Am. J. Respir. Crit. Care Med., 158, pp. 1945-1950, 1998.	<input type="checkbox"/>	<input type="checkbox"/>
	15.	Vining, R. and McGinley, RA, "Hormones in Saliva", Critical Reviews in Clinical Laboratory Science, 23, pp. 95-146, 1985.	<input type="checkbox"/>	<input type="checkbox"/>
	16.	Welgus HG et al., "Human Skin Fibroblast Collagenase Interaction with Substrate and Inhibitor", Coll. Relat. Res., 5, pp. 167-179, 1985.	<input type="checkbox"/>	<input type="checkbox"/>
	17.	Wolff, K. et al., Hay, A., "Methadone in Saliva", Clinical Chemistry, 37, pp. 1297-1298, 1991.	<input type="checkbox"/>	<input type="checkbox"/>
	18.	Garrett, C. Durkan et al., "Prognostic Significance of Matrix Metalloproteinase-1 and Tissue Inhibitor of Metalloproteinase-1 in Voided Urine Samples from Patients with Transitional Cell Carcinoma of the Bladder", Clin. Cancer Res., 7, pp. 3450-3456, Nov. 2001.	<input type="checkbox"/>	<input type="checkbox"/>
	19.	Birkedal-Hansen, H. et al., "Matrix Metalloproteinases: A Review", Crit. Rev. Oral. Biol. Med., 4(2), pp 197-250, 1993.	<input type="checkbox"/>	<input type="checkbox"/>
✓	20.	McCarthy K. et al., "High Levels of Tissue Inhibitor of Metalloproteinase-1 Predict Poor Outcome in Patients with Breast Cancer", Int. J. Cancer, 84, pp. 44-48, 1999.	<input type="checkbox"/>	<input type="checkbox"/>
			<input type="checkbox"/>	<input type="checkbox"/>
			<input type="checkbox"/>	<input type="checkbox"/>
			<input type="checkbox"/>	<input type="checkbox"/>

EXAMINER SIGNATURE

1

DATE CONSIDERED

3/24/06

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.